DOCSLIB.ORG

ACCGE 2015 Abstracts Ebook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACCGE 2015 Abstracts Ebook Table of Contents Introduction/Plenary Correlated Electron Crystals 1 Detector Materials: Scintillators and Semiconductors (ACCGE) 1 Fundamentals of Crystal Growth (ACCGE) 1 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 1 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 1 Correlated Electron Crystals 2 Detector Materials: Scintillators and Semiconductors (ACCGE) 2 Fundamentals of Crystal Growth (ACCGE) 2 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 2 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 2 Detector Materials: Scintillators and Semiconductors (ACCGE) 3 Fundamentals of Crystal Growth (ACCGE) 3 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 3 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 3 Poster Session 1 III-Vs on Silicon (Joint ACCGE/OMVPE) 1 Young Author and AACG Awards Detector Materials: Scintillators and Semiconductors (ACCGE) 4 Fundamentals of Crystal Growth (ACCGE) 4 III-Vs on Silicon (Joint ACCGE/OMVPE) 2 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 4 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 4 Nonlinear Optical and Laser Host Materials (ACCGE) 1 Thin Film Growth, Epitaxy, and Superlattices (Joint ACCGE/OMVPE) 1 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 5 III-V Nitride, SiC, and Other Wide Bandgap Materials (Joint ACCGE/OMVPE) 5 Materials for Photovoltaics and Energy Technology (Joint ACCGE/OMVPE) 1 Nonlinear Optical and Laser Host Materials (ACCGE) 2 Thin Film Growth, Epitaxy, and Superlattices (Joint ACCGE/OMVPE) 2 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 6 Poster Session 2 Materials for Photovoltaics and Energy Technology (Joint ACCGE/OMVPE) 2 Materials for Photovoltaics and Energy Technology (Joint ACCGE/OMVPE) 3 Nonlinear Optical and Laser Host Materials (ACCGE) 3 Second Symposium on 2D Electronic Materials (Joint ACCGE/OMVPE) 7 Thin Film Growth, Epitaxy, and Superlattices (Joint ACCGE/OMVPE) 3 Nonlinear Optical and Laser Host Materials (ACCGE) 4 Thin Film Growth, Epitaxy, and Superlattices (Joint ACCGE/OMVPE) 4 Materials for Photovoltaics and Energy Technology (Joint ACCGE/OMVPE) 4 Bulk Crystal Growth 1 Industrial Crystal Growth Technologies and Equipment (ACCGE) 1 Biological, Biomimetic, and Organic Crystallization (ACCGE) 1 OMVPE of Compound Semiconductors for Optoelectronics 1 OMVPE of Compound Semiconductors for Optoelectronics 2 Bulk Crystal Growth 2 Industrial Crystal Growth Technologies and Equipment (ACCGE) 2 Biological, Biomimetic, and Organic Crystallization (ACCGE) 2 Bulk Crystal Growth 3 Industrial Crystal Growth Technologies and Equipment (ACCGE) 3 Novel OMVPE Techniques and In-Situ Monitoring Biological, Biomimetic, and Organic Crystallization (ACCGE) 3 Bulk Crystal Growth 4 Industrial Crystal Growth Technologies and Equipment (ACCGE) 4 Nanocrystals, Quantum Dots and Nanowires (Joint ACCGE/OMVPE) 1 Biological, Biomimetic, and Organic Crystallization (ACCGE) 4 Bulk Crystal Growth 5 Industrial Crystal Growth Technologies and Equipment (ACCGE) 5 Nanocrystals, Quantum Dots and Nanowires (Joint ACCGE/OMVPE) 2 Biological, Biomimetic, and Organic Crystallization (ACCGE) 5 Bulk Crystal Growth 6 Nanocrystals, Quantum Dots and Nanowires (Joint ACCGE/OMVPE) 3 Biological, Biomimetic, and Organic Crystallization (ACCGE) 6 Monday, August 3, 2015 8:00 AM - 10:00 AM Introduction/Plenary Location: Missouri Session Chair(s): Joan Redwing, Luke Mawst 8:30 AM - 9:15 AM GIANT CRYSTALS OF NAICA: THE SCIENCE BEHIND THE BEAUTY Invited Juan M. Garcia-Ruiz Consejo Superior de Investigaciones Cientificas, Armilla (Granada), Spain GIANT CRYSTALS OF NAICA: THE SCIENCE BEHIND THE BEAUTY Juan Manuel García-Ruiz Laboratorio de Estudios Cristalográficos, Instituto Andaluz de Ciencias de la Tierra, CSIC-Universidad de Granada, Granada, Spain Crystals are everywhere in our day life, but only in a very few cases do they reveal themselves as the large polyhedra that have fascinated mankind since remote times. Even rarer is to find colossal crystals other than those dreamed up in literature and comic masterpieces. However, there are exceptions. The Cave of Giant Crystals in the Naica mine (Mexico) is one of the most amazing displays of mineral beauty ever created by nature. In addition to the colossal columnar crystals of gypsum (CaSO4 2H2O), which in some cases exceed eleven meters in length and one meter in thickness, the scenery developed by the crystalline beams of moonlight luster going through the darkness of the cave, from the floor to the ceiling, is a unique example of harmony based on crystal symmetry. At the same time, deciphering the formation mechanism of these crystals is a fascinating challenge. In this lecture I will review the nucleation and growth of gypsum crystals as the scientific basis for the formation of this remarkable phenomenon of mineralization. References: [1] García-Ruiz JM, Ayora C, Canals A, Otálora F, Geology 35 (2007) 327. [2] Van Driessche A, García-Ruiz JM, Tsukamoto K, Patiño LD, Satoh H, PNAS 108 (2011) 1572 [3] Otálora F & Garcia-Ruiz JM, Chem. Soc. Rev 43 (2014) 2013. 9:15 AM - 10:00 AM AlGaN-BASED TECHNOLOGY: STATE-OF-THE-ART AND REMAINING CHALLENGES Invited Zlatko Sitar North Carolina State University, Raleigh, NC AlGaN alloys are the building blocks of deep UV optoelectronics and high-power devices. It has been demonstrated that the highest crystalline quality AlGaN films with high Al content are obtained on AlN single crystal substrates. Recently, UV LEDs emitting at 265 nm with output powers exceeding 80 mW and high reliability, as well as low-threshold, optically pumped lasers emitting at wavelengths between 230-280 nm have been demonstrated. These results demonstrate the advantages of using AlN substrates for this technology. Despite the encouraging results, challenges in strain management and management of point defects pose the remaining limitations of this technology. Pseudomorphic AlGaN films with dislocation densities lower than 1E3 cm-2 have been achieved, sustaining compressive stresses with thicknesses exceeding 3 µm. If relaxation is not essential for a given application, relaxation schemes can be avoided altogether in favor of pseudomorphic AlGaN films on AlN. As single-crystal AlN substrates have low dislocation densities, of the order of 1E3 cm-2, it is unrealistic to expect sufficient strain accommodation through dislocation bending of pre-existing dislocations. This makes misfit dislocation nucleation an essential mechanism in the relaxation of these films. Composition and strain relaxation in high Al content AlGaN layers grown by MOCVD on AlN substrates will be discussed with respect to the substrate miscut. It was found that the nucleation of misfit dislocations in AlGaN layers depends on the presence of either macrosteps or bilayer steps on the growth surface. As miscut controls the surface step morphology, it plays a crucial role in misfit dislocation nucleation and alloy critical thickness. Following these results, dislocation densities below 105 cm-2 have been obtained in these films for Al content higher than 60%. These low dislocation densities allowed for a systematic approach to the identification and control of compensating point defects that affect n-type conductivity. This approach has been guided by a first-principles-based database that combines point defect data to predict defect concentrations and significant optical transitions for defect identification. This is currently guiding the development of the Fermi level control scheme for point defect management that has allowed for the achievement of high free carrier concentrations in high Al content AlGaN films. The talk will discuss MOCVD processes for control of AlGaN composition and heteroepitaxy, approaches to control strain, point defects, and doping in this material, and implications of this technology for further development of UV optoelectronic and electronic devices. Monday, August 3, 2015 10:30 AM - 12:00 PM Correlated Electron Crystals 1 Location: Lake/Canyon Session Chair(s): Athena Safa-Sefat, John E. Greedan 10:30 AM - 11:00 AM SYNTHESIS, CRYSTAL GROWTH, AND STRUCTURAL CHARACTERIZATION OF NOVEL ZINTL PHASES OF AS, SB AND BI WITH THE D-METALS Invited Svilen Bobev University of Delaware, Newark, DE The crystal chemistry of the intermetallic compounds containing metals with different electronegativities presents a combination of diverse and complicated bonding patterns and unique metal-metal interactions. As part of an ongoing effort to better understand the structure-property relationships in such intermetallics containing d- and/or f-elements, we focused our attention on the ternary systems A-M-As, A-M-Sb and A-M-Bi (A = alkali, alkaline-earth metals, and/or rare-earth metal; M = Mn, Zn, Cd). Recent experimental work carried out by our group led to the discovery of several new classes of transition metal based compounds. Common threads in the structures of all of these are the M-centered tetrahedra of As, Sb or Bi, respectively, which are interconnected through shared corners or edges to form chains, ribbons, or layers with complex topologies. These systems present a case where a strikingly delicate balance between the packing efficiency (size effects) and the valence electron concentration (electronic effects) governs the stability of a particular arrangement over another. The structural relationship between these and some well-known structures with two-dimensional
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Fabrication and Characterization of Rare-Earth Silicide Thin Films
    UNIVERSITÉ CATHOLIQUE DE LOUVAIN Ecole Polytechnique de Louvain ICTEAM Fabrication and characterization of rare-earth silicide thin films Dissertation présentée en vue de l’obtention du grade de Docteur en Sciences de l’Ingénieur par Nicolas Reckinger Promoteurs: Prof. Vincent Bayot Prof. Jean-Pierre Raskin Février 2011 UNIVERSITÉ CATHOLIQUE DE LOUVAIN Ecole Polytechnique de Louvain ICTEAM Fabrication and characterization of rare-earth silicide thin films Dissertation présentée en vue de l’obtention du grade de Docteur en Sciences de l’Ingénieur par Nicolas Reckinger Membres du jury: Prof. Vincent Bayot, promoteur Prof. Jean-Pierre Raskin, promoteur Prof. Emmanuel Dubois Prof. Denis Flandre Dr. Thierry Baron Prof. Siegfried Mantl Dr. Xiaohui Tang Prof. Danielle Vanhoenacker-Janvier, président Février 2011 Abstract With the continuous reduction of the dimensions of metal-oxide- semiconductor field-effect transistors (MOSFET), issues related to the formation of source and drain contacts by ion implantation appear. A new source and drain architecture based on metallic contacts over silicon was proposed to replace conventional highly doped extensions. To real- ize such a device, the so-called Schottky barrier (SB) MOSFET, requires working with materials presenting low Schottky barrier heights (SBH) to silicon. For n-type MOSFETs, rare-earth silicides, alloys between silicon and a rare-earth metal, are the best candidates. For Schottky barrier MOSFETs to compete with conventional ones in terms of on- and off- currents, the SBH of rare-earth silicides is intrinsically still too high and must accordingly be further reduced. Such a barrier decrease can be achieved with the dopant segregation technique, where a thin dopant layer is interposed between the silicide and silicon.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,601,755 Mélard Et Al
    United States Patent (19) 11 Patent Number: 4,601,755 Mélard et al. 45 Date of Patent: Jul. 22, 1986 (54) CERIUM BASED GLASSPOLISHING (56) References Cited COMPOSITIONS U.S. PATENT DOCUMENTS 75 Inventors: Pierre Mélard, Lagord; Marcel 3,262,766 7/1966 Nonamaker ........... ... 51/309 Peltier, La Rochelle; Francis Tastu, 3,768,989 10/1973 Goetzinger et 51/309 Nieul/sur/Mer, all of France 4,161,463 7/1979 Myers et al... ... SO2/263 73 Assignee: Rhone-Poulene Specialites 4,62,921 7/1979 Litvinov et al. P ... O - 0 - - - - - - - - - - - A as - - 50/9 Chimiques, Courbevoie, France Primary Examiner-Amelia B. Yarbrough Attorney, Agent, or Firm-Burns, Doane, Swecker & 21 Appl. No.: 635,828 Mathis 22 Filed: Jul, 30, 1984 57 ABSTRACT (30) Foreign Application Priority Data Cerium based glass polishing compositions, well adapted for the polishing, e.g., of optical glass, are com Jul. 29, 1983 FR France ................................ 83 2519 prised of (i) at least one crystalline phase of CeO2 type, 51) Int. Cl'................................................ C09G 1/02 and (ii) a crystalline phase which comprises a rare earth 52 U.S. C. ........................................ 106/3; 51/308; pyrosilicate having the formula Ln2-CeSi2O7, 51/309; 156/DIG. 63; 423/263 wherein Ln is at least one lanthanide or yttrium and x is 58 Field of Search ................... 106/3, 288 B, 287.34; a number ranging from zero to less than 2. 51/309, 308; 423/263; 156/DIG. 63; 502/263, 302, 304,303 59 Claims, No Drawings 4,601,755 1. 2 forming insoluble rare earth compounds, with the num CERIUM BASED GLASS POLISHING ber of equivalents of base being greater than or equal to COMPOSITIONS the number of equivalents of cerium and the pH of the reaction medium being higher than 6; BACKGROUND OF THE INVENTION 5 (b) the resultant precipitate is filtered; 1.
    [Show full text]
  • Topical Pharmaceutical Compositions
    Europâisches Patentamt 0 085 579 ® ê European Patent Office @ Publication number: B1 Office européen des brevets ® EUROPEAN PATENT SPECIFICATION @ Date of publication of patent spécification: 06.05.87 ® Intel.4: A 61 K 45/06, A 61 K 31/195, A 61 K 31/20, A 61 K 31/375, (H) Application number: 83300531.7 A 61 K 31/585, A 61 K 31/19, © Date offiling: 02.02.83 A 61 K 31/61, A 61 K 31/355, A 61 K 31/715, A 61 K 33/30, A 61 K 35/78 (54) Topical pharmaceutical compositions. (§) Priority: 03.02.82 US 345204 (73) Proprietor: EFAMOL LIMITED 12th Floor Moor House London Wall London EC2Y 5HE (GB) (§) Date of publication of application: 10.08.83 Bulletin 83/32 ® Inventor: Horrobin, David Frederick P.O.Box 10 Nuns Island (§) Publication of the grant of the patent: Montréal H3E 1 J8 (CA) 06.05.87 Bulletin 87/19 Inventor: Lieb, Julian 41 Village Lane Bethany Connecticut 06525 (US) (S) Designated Contracting States: AT BE CH DE FR GB IT Ll LU NL SE (74) Représentative: Cockbain, Julian Roderick Michaelson et al - (§) Références cited: Frank B. Dehn & Co. European Patent Attorneys EP-A-0 068854 Impérial House 15-19, Kingsway US-A-3 639 625 London WC2B 6UZ (GB) US-A-4328243 CÛ O) in LO oo o o Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
    US 20160354315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub. Date: Dec. 8, 2016 (54) DOSAGE FORMS AND USE THEREOF Publication Classification (71) Applicant: Triastek, Inc., Nanjing (CN) (51) Int. Cl. A69/20 (2006.01) (72) Inventor: Xiaoling Li, Dublin, CA (US) A6IR 9/24 (2006.01) A63L/92 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/173,596 CPC ........... A61K 9/2031 (2013.01); A61K 9/2027 (2013.01); A61K 31/192 (2013.01); A61 K 9/209 (2013.01) (22) Filed: Jun. 3, 2016 (57) ABSTRACT The present disclosure provides a stable solid pharmaceuti Related U.S. Application Data cal dosage form for oral administration. The dosage form includes a Substrate that forms at least one compartment and (60) Provisional application No. 62/170,645, filed on Jun. a drug content loaded into the compartment. The dosage 3, 2015, provisional application No. 62/313,092, filed form is so designed that the active pharmaceutical ingredient on Mar. 24, 2016. of the drug content is released in a controlled manner. Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 A1 FG. A F.G. B. Peak carcetitration, tax ise F.G. C Patent Application Publication Dec. 8, 2016 Sheet 2 of 20 US 2016/0354315 A1 F.G. 2B Patent Application Publication Dec. 8, 2016 Sheet 3 of 20 US 2016/0354315 A1 F.G. 3 Patent Application Publication Dec. 8, 2016 Sheet 4 of 20 US 2016/0354315 A1 Patent Application Publication Dec.
    [Show full text]
  • Hydrothermal Crystal Growth of Metal Borates for Optical Applications Carla Heyward Clemson University, [email protected]
    Clemson University TigerPrints All Dissertations Dissertations 8-2013 Hydrothermal Crystal Growth of Metal Borates for Optical Applications Carla Heyward Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Chemistry Commons Recommended Citation Heyward, Carla, "Hydrothermal Crystal Growth of Metal Borates for Optical Applications" (2013). All Dissertations. 1164. https://tigerprints.clemson.edu/all_dissertations/1164 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. HYDROTHERMAL CRYSTAL GROWTH OF METAL BORATES FOR OPTICAL APPLICATIONS A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Chemistry by Carla Charisse Heyward August 2013 Accepted by: Dr. Joseph Kolis, Committee Chair Dr. Shiou-Jyh Hwu Dr. Andrew Tennyson Dr. Gautam Bhattacharyya ABSTRACT Crystals are the heart of the development of advance technology. Their existence is the essential foundation in the electronic field and without it there would be little to no progress in a variety of industries including the military, medical, and technology fields. The discovery of a variety of new materials with unique properties has contributed significantly to the rapidly advancing solid state laser field. Progress in the crystal growth methods has allowed the growth of crystals once plagued by difficulties as well as the growth of materials that generate coherent light in spectral regions where efficient laser sources are unavailable. The collaborative progress warrants the growth of new materials for new applications in the deep UV region.
    [Show full text]
  • CHRONIC MEDICATION COMPREHENSIVE FORMULARY Effective 1 June 2013
    CHRONIC MEDICATION COMPREHENSIVE FORMULARY Effective 1 June 2013 This formulary represents drugs covered for chronic use for 25 Chronic Disease List (CDL) conditions and individual Diagnosis and Treatment Pairs (DTP) conditions. Reimbursement of medicines for non-CDL and non-DTP conditions is subject to Scheme Rules and the Metropolitan Health Risk Management Medicine Reimbursement Policy. Unless stipulated, all active ingredients listed in this formulary are subject to the Metropolitan Health Reference Price (MetRef). The examples below serve as a guide on the trade names available for the active ingredients listed and not for marketing a specific brand. Any product within the MetRef category may be used, however a co-payment may be attracted if the product selected is above the generic reference threshold. The dispensing pharmacist may make a generic substitution to assist members in avoiding a co-payment. Treatment designated as "Accepted treatment" indicates that this is a medicine covered as first line, according to the Metropolitan Health Risk Management Medicine Reimbursement Policy. For treatment designated as "Motivation required", certain criteria as specified in the Metropolitan Health Risk Management Medicine Reimbursement Policy should be met. For treatment designated as "Special investigation", the relevant clinical investigation reports as specified in the Metropolitan Health Risk Management Medicine Reimbursement Policy are required. Abbreviations of dosage form CAP Capsule ENE Enema OPD Eye drops CPS Capsule
    [Show full text]
  • Crystal Growth of Quantum Magnets in the Rare-Earth Pyrosilicate Family R2si2o7 (R = Yb, Er) Using the Optical Floating Zone Method
    crystals Article Crystal Growth of Quantum Magnets in the Rare-Earth Pyrosilicate Family R2Si2O7 (R = Yb, Er) Using the Optical Floating Zone Method Harikrishnan S. Nair 1,2, Tim DeLazzer 1, Tim Reeder 1, Antony Sikorski 1, Gavin Hester 1 and Kate A. Ross 1,* 1 Department of Physics, Colorado State University, 200 W. Lake St., Fort Collins, CO 80523-1875, USA; [email protected] (T.D.); [email protected] (T.R.); [email protected] (A.S.); [email protected] (G.H.) 2 Department of Physics, 500 W. University Ave, The University of Texas at El Paso, El Paso, TX 79968, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-970-491-5370 Received: 23 March 2019; Accepted: 2 April 2019; Published: 7 April 2019 Abstract: We report on the crystal growth of rare-earth pyrosilicates, R2Si2O7 for R = Yb and Er using the optical floating zone method. The grown crystals comprise members from the family of pyrosilicates where the rare-earth atoms form a distorted honeycomb lattice. C-Yb2Si2O7 is a quantum dimer magnet with field-induced long range magnetic order, while D-Er2Si2O7 is an Ising-type antiferromagnet. Both growths resulted in multi-crystal boules, with cracks forming between the different crystal orientations. The Yb2Si2O7 crystals form the C-type rare-earth pyrosilicate structure with space group C2/m and are colorless and transparent or milky white, whereas the Er-variant 3+ is D-type, P21/b, and has a pink hue originating from Er . The crystal structures of the grown single crystals were confirmed through a Rietveld analysis of the powder X-ray diffraction patterns from pulverized crystals.
    [Show full text]
  • Treatments for Atopic Eczema
    Health Technology Assessment 2000; Vol. 4: No. 37 Review Systematic review of treatments for atopic eczema C Hoare A Li Wan Po H Williams Health Technology Assessment NHS R&D HTA Programme HTA HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph. You can order HTA monographs from our Despatch Agents: – fax (with credit card or official purchase order) – post (with credit card or official purchase order or cheque) – phone during office hours (credit card only). Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: HTA Despatch Email: [email protected] c/o Direct Mail Works Ltd Tel: 02392 492 000 4 Oakwood Business Centre Fax: 02392 478 555 Downley, HAVANT PO9 2NP, UK Fax from outside the UK: +44 2392 478 555 NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles).
    [Show full text]
  • Medicines (Prescription Only) (Jersey) Order 1997
    MEDICINES (PRESCRIPTION ONLY) (JERSEY) ORDER 1997 Revised Edition 20.625.95 Showing the law as at 1 January 2019 This is a revised edition of the law Medicines (Prescription Only) (Jersey) Order 1997 Arrangement MEDICINES (PRESCRIPTION ONLY) (JERSEY) ORDER 1997 Arrangement Article 1 Interpretation ................................................................................................... 5 2 Prescription only medicines ............................................................................ 7 3 Medicinal products that are not prescription only medicines ......................... 8 4 New medicinal products ................................................................................. 9 5 Appropriate practitioner .................................................................................. 9 6 Conditions for prescriptions relating to sale and supply ................................. 9 6A Conditions for prescriptions – administration ............................................... 11 7 Exemption for highly diluted medicinal products ........................................ 11 8 Exemptions for specified categories of persons ............................................ 11 9 Exemption for emergency sale or supply...................................................... 12 10 Exemption for sale or supply in hospitals or the prison................................ 14 11 Exemption for authorised needle supply services ......................................... 14 12 Exemption for sale or supply in cases involving another’s default
    [Show full text]